CosmoFarm Delivers Record Q2 2026 Revenue of Over $15M, Representing $60+ Million Annualized Run-Rate; Adds Over 80 Pharmacies and Expands AI Automation and Facility Capacity
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported that subsidiary CosmoFarm achieved record Q2 2026 revenue of over $15 million, implying an annualized run-rate above $60 million.
CosmoFarm added 80+ pharmacies, and Cosmos Health is boosting capital expenditure for AI-driven robotic automation and facility expansion to support volume growth, efficiency and margins.
Positive
- CosmoFarm Q2 2026 revenue exceeded $15 million
- Annualized revenue run-rate now above $60 million
- Over 80 new pharmacies added to distribution network
- Increased investment in AI and robotic automation
- Facility expansion to handle higher order volumes
Negative
- Higher capital expenditure required at CosmoFarm
News Market Reaction – COSM
In the Jun 18 session, COSM declined 11.92%, reflecting a significant negative market reaction. Argus tracked a trough of -16.7% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 17 | Manufacturing contract | Positive | -3.2% | Five-year Pharmex deal for 2.86M dermatology units via Cana facility. |
| Jun 15 | US portfolio update | Positive | +14.2% | 18 Series nutraceutical launch with projected $22.7M revenue and $17.0M profit. |
| Jun 12 | Manufacturing orders | Positive | +1.6% | New Cana orders totaling 253,657 units across multiple medicines. |
| Jun 12 | Brand sales update | Positive | +1.6% | C-Scrub and C-Sept annualized sales above $1.5M with >70% margins. |
| Jun 11 | Acquisition LOI | Positive | -9.7% | LOI to acquire Doc Pharma with $24M assets and $3.2M gross profit. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent COSM news has produced mixed reactions, with most growth updates aligning positively but some sizeable divergences on accretive deals and contracts.
Key Terms
annualized run-rate financial
capital expenditure financial
robotic automation technical
artificial intelligence technical
unit economics financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, CosmoFarm S.A. (“CosmoFarm”), delivered record revenue of over
CosmoFarm added more than 80 new pharmacies to its distribution network during the period, continuing the strong customer growth that has made it one of the leading pharmaceutical wholesalers in the greater Athens area.
To support this accelerating growth, Cosmos Health is increasing capital expenditure at CosmoFarm, investing in new robotic automation and artificial intelligence systems to enhance procurement, inventory management, and order fulfillment. The Company is also expanding the size of the CosmoFarm facility to accommodate higher volumes and continued network expansion.
These investments build on CosmoFarm’s existing automated infrastructure, including ROWA and SSI SCHÄFER A-frame robotic systems, which have driven improvements in operational efficiency, unit economics, and profitability per customer.
Greg Siokas, CEO of Cosmos Health, stated: "CosmoFarm’s record second quarter marks an important milestone, with revenue reaching an annualized run-rate of over
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
